

Wednesday, 7 September 2022

INCLUSION IN S&P/ASX 300 INDEX

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or **Company**) is pleased to advise shareholders that it has been notified that, effective prior to market open on 19 September 2022, it will form part of the S&P/ASX 300 Index.

– ENDS –

This announcement was authorised for release to ASX by the Company Secretary of ACL.

For further information regarding this announcement, please contact:

Investors

Eleanor Padman

Company Secretary

Email: investors@clinicallabs.com.au

Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.